Answers are grounded in this paper and cite their sources.
Background: Adverse events due to plateletpheresis are not unheard of, citrate-related reactions being the most common. Most of these events are mild and self-limiting. The current study describes adverse events in plateletpheresis using modern apheresis systems. Materials and Methods: The prospective study included 1455 plateletpheresis procedures from July 2013 to April 2016. Procedures were performed on Amicus, Trima Accel and Cobe spectra cell separators. The endpoint of each procedure was a yield of 3 × 1011 platelets (PLTs) per unit. Donor adverse reaction if any was managed, reported, and documented. Results: The median age of donors was 31 years with male-to-female ratio of 13:1. The median body surface area and body mass index were 1.64 m2 and 22.4 kg/m2, respectively. The mean PLT count of donors was 199.8 × 103/uL with a mean hemoglobin value of 13.6 g/dl. ACD infusion was significantly more in the Cobe (P < 0.01). Donation time was least with the Trima compared to Amicus (P < 0.01) and Cobe (P < 0.001). Total whole blood volume processed was higher in Cobe (P < 0.01). Paresthesia due to citrate toxicity was the most common adverse reaction (65.3%), and vascular injury was observed in only five donors. Adverse reaction was significantly more with the Cobe (P < 0.01). The overall incidence of adverse reaction was 3.4%. Conclusion: Serious adverse events were not observed. The modern-generation apheresis machines are more donor-friendly and cause less adverse reactions compared to the older versions. Good donor screening, optimized donor physiognomic and hematological values, and skilled operator are the key factors to reaction reduction by apheresis.
No takes yet. Share an insight, caveat, or question.
Das et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: